Previous 10 | Next 10 |
home / stock / ate:cc / ate:cc news
Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite Canada NewsWire TORONTO , Aug. 21, 2023 /CNW/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview ...
- Otenaproxesul new formulation tablets manufactured for upcoming PK/PD study - PK/PD study results expected next quarter with Phase II initiation in calendar Q1 2024 - Ended quarter with $34.3 million in cash and equivalents Antibe Therapeutics Inc. (TSX: ATE, OTCQX: AT...
- Completed transition to otenaproxesul’s new formulation; tablet manufacturing underway - PK/PD study results expected in calendar Q4 2023 with Phase II initiation in Q1 2024 - Ended year with $38.9 million in cash and equivalents Antibe Therapeutics Inc. (TSX: ATE, OTCQX: A...
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the Precision in Clinical Trials Summit being held in Boston on May 1 ȁ...
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference being held in...
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update. CRO Selected for PK/PD Study for Otenaproxesul’s New Formu...
- Recent animal data on otenaproxesul's new formulation confirm rapid drug uptake and potential for effective pain management - Targeting first clinical dose in calendar Q3 2023; Phase II top-line data within 12 months - Ended quarter with $42.4 million in cash and equivalents, provid...
- Progress includes otenaproxesul’s new formulation, strengthened IP and robust third-party sales projections - Sale of Citagenix subsidiary provides non-dilutive funding - Ended quarter with $45.4 million in cash and equivalents, providing over two ye...
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to announce the closing of the sale of its Citagenix Inc. subsidiary to HANSAmed Limited (...
- Patent application filed for improved formulation; strengthens IP protection to 2042 - Anticipated benefits include faster onset of action, lower doses - Phase II molar study no longer required; Phase II bunionectomy study on track for H1 2023 A...
News, Short Squeeze, Breakout and More Instantly...
Antibe Therapeutics Inc. Company Name:
ATE:CC Stock Symbol:
TSXC Market:
Antibe Therapeutics Inc. Website:
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE) announced that the Company’s request for an extension of its previously announced stay of proceedings under the Companies’ Creditors Arrangement Act (the “ CCAA ”...
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE) announced that the Company sought an extension of its previously announced stay of proceedings (“ Stay ”) under the Companies’ Creditors Arrangement Act (the “ ...
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE) announced that the Toronto Stock Exchange (“TSX”) is reviewing the eligibility for continued listing on the TSX of the securities of the Company. The TSX has identified the Compan...